Stealth BioTherapeutics Corp. ADS - ADR Key Ratios

$0.32

$0.00 (0.00%)

As on 16-Nov-2022 09:30EDT

Market cap

info icon

$24 Mln

Revenue (TTM)

info icon

$0 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

36.6

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue -- -- -- -- --
EBIT -- -- 33.04 19.13 4.42
Net Profit 59.59 -5.81 -6.79 15.90 2.65
EPS 61.61 4.77 9.47 24.69 --
Book Value -- -- -- -- --
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMDec-21Dec-20
EBIT-Margin info -308.54-308.54------
Net Margin info ----------
Return on equity info -479.69-275.49--188.72-1,666.63
Return on Capital info 7.5720.00--318.24-357.58
Return on Assets info -153.97-424.92-108.34-122.05-129.71
Debt to Equity (x) info -----0.26-0.30-0.87
ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
Stealth BioTherapeutics Corp. ADS - ADR
--
318.24
-357.58
62.06
39.32
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

--

--

Profit after tax / Average Net worth * 100

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
Stealth BioTherapeutics Corp. ADS - ADR
--
188.72
-1,666.63
38.83
28.53
Peer Median
-26.31
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

-108.34

Lower than Peers by 95.38

Profit after tax / Average Total assets * 100

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
Stealth BioTherapeutics Corp. ADS - ADR
-108.34
-122.05
-129.71
-210.14
-852.93
Peer Median
-12.96
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

--

--

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
Stealth BioTherapeutics Corp. ADS - ADR
--
--
--
-308.54
--
Peer Median
-59.70
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

--

--

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
Stealth BioTherapeutics Corp. ADS - ADR
--
--
--
-340.15
--
Peer Median
-71.06
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Revenue Growth

--

--

Year on year growth in net sales

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
Stealth BioTherapeutics Corp. ADS - ADR
--
--
-1.00
--
--
Peer Median
20.56
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

33.04

Higher than Peers by 17.84

Year on year growth in operating profit (EBIT)

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
Stealth BioTherapeutics Corp. ADS - ADR
33.04
4.60
25.41
13.35
5.75
Peer Median
15.20
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

-6.79

Lower than Peers by 14.65

Year on year growth in profit after tax

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
Stealth BioTherapeutics Corp. ADS - ADR
-6.79
8.58
19.90
25.83
-16.65
Peer Median
7.86
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

9.47

Lower than Peers by 20.99

Year on year growth in earnings per share

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
Stealth BioTherapeutics Corp. ADS - ADR
9.47
0.26
0.46
0.86
--
Peer Median
30.45
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

-289.81

Lower than Peers by 291.06

Year on year growth in book value per share

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
Stealth BioTherapeutics Corp. ADS - ADR
-289.81
--
--
--
--
Peer Median
1.25
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Debt to Equity

-0.26

--

Total debt / Net worth

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
Stealth BioTherapeutics Corp. ADS - ADR
-0.26
-0.30
-0.87
0.94
-0.32
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

--

--

(Short term borrowings / Net worth)

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
Stealth BioTherapeutics Corp. ADS - ADR
--
--
--
0.85
-0.02
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

3.68

Higher than Peers by 0.20

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
Stealth BioTherapeutics Corp. ADS - ADR
3.68
4.58
1.66
1.54
0.33
Peer Median
3.48
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

3.68

Higher than Peers by 0.39

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
Stealth BioTherapeutics Corp. ADS - ADR
3.68
--
--
--
--
Peer Median
3.29
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

-34.72

Lower than Peers by 33.21

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
Stealth BioTherapeutics Corp. ADS - ADR
-34.72
-37.28
-26.84
-9.76
-3.52
Peer Median
-1.51
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Asset Turnover

--

--

Sales / Average Total Assets

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
Stealth BioTherapeutics Corp. ADS - ADR
--
--
--
0.62
--
Peer Median
0.23
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Earnings

--

--

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
Stealth BioTherapeutics Corp. ADS - ADR
--
-0.90
-1.20
-1.41
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

36.57

Higher than Peers by 31.61

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
Stealth BioTherapeutics Corp. ADS - ADR
36.57
-1.04
-6.63
5.85
--
Peer Median
4.96
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

--

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
Stealth BioTherapeutics Corp. ADS - ADR
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

-0.07

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
Stealth BioTherapeutics Corp. ADS - ADR
-0.07
-0.30
-0.93
-1.03
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

24

Lower than Peers by 60

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
Stealth BioTherapeutics Corp. ADS - ADR
24
--
--
--
--
Peer Median
83
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...